dasatinib + dasatinib

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myeloid Leukemia, Chronic, Accelerated Phase

Conditions

Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Trial Timeline

Jun 1, 2005 → Jun 1, 2013

NCT ID

NCT00123487

About dasatinib + dasatinib

dasatinib + dasatinib is a phase 3 stage product being developed by Bristol Myers Squibb for Myeloid Leukemia, Chronic, Accelerated Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT00123487. Target conditions include Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00482703	Phase 1/2	Completed	May 1, 2007	May 1, 2009	Myeloid Leukemia, Chronic
NCT00385580	Phase 2	Completed	Jan 1, 2007	Oct 1, 2010	Prostate Cancer
NCT00371254	Phase 2	Completed	Dec 1, 2006	Sep 1, 2008	Breast Cancer
NCT00123487	Phase 3	Completed	Jun 1, 2005	Jun 1, 2013	Myeloid Leukemia, Chronic, Accelerated Phase

Competing Products

20 competing products in Myeloid Leukemia, Chronic, Accelerated Phase

See all competitors

Product	Company	Stage	Hype Score
AFM28	Affimed	Phase 1	25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen	CSPC Pharmaceutical Group Limited	Phase 2	51
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
PRGN-3006 T Cells	Precigen	Phase 1	28
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine	Race Oncology	Phase 1	25
ZN-d5 ZN-c3 + ZN-c3	Zentalis Pharmaceuticals	Phase 1/2	33
ZN-d5	Zentalis Pharmaceuticals	Phase 1	25
VIP943 (QW) + VIP943 (BIW)	Vincerx Pharma	Phase 1	25
Tomivosertib	eFFECTOR Therapeutics	Phase 1	25
gemtuzumab ozogamycin	Chugai Pharmaceutical	Phase 3	77
Quizartinib High Dose + Quizartinib Low Dose	Daiichi Sankyo	Phase 2	52
Decitabine + Quizartinib + Venetoclax	Daiichi Sankyo	Phase 1/2	41
Milademetan	Daiichi Sankyo	Phase 1	33
Quizartinib + Treatment according to Physician's Choice + Standard of Care Chemotherapy	Daiichi Sankyo	Phase 3	77
Quizartinib + Cytarabine + Idarubicin + Daunorubicin	Daiichi Sankyo	Phase 1	33
AC220	Daiichi Sankyo	Phase 2	52
PLX3397 + PLX3397	Daiichi Sankyo	Phase 1/2	41
Quizartinib	Daiichi Sankyo	Phase 2	52
Quizartinib	Daiichi Sankyo	Phase 1	33
Quizartinib + Fludarabine + Cytarabine + Idarubicin + glycosylated G-CSF	Daiichi Sankyo	Phase 1/2	41

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved